ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
GRI Bio Inc

GRI Bio Inc (GRI)

0.863
0.0264
( 3.16% )
업데이트: 00:48:16

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
0.863
매수가
0.835
매도가
0.863
거래량
111,493
0.81 일간 변동폭 0.863
0.3015 52주 범위 115.57
전일 종가
0.8366
개장가
0.8551
최근 거래 시간
100
@
0.863
마지막 거래 시간
00:48:16
평균 볼륨(3m)
4,767,134
재정 규모
US$ 94,159
VWAP
0.844526

GRI 최신 뉴스

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment...

GRI Bio Announces Exercise of Warrants

LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis Company...

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

LA JOLLA, CA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE...

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker study evaluating lead program GRI-0621 for the...

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.167-16.2135922331.031.030.797178220.92247149CS
40.488130.1333333330.3751.790.355101119619861.0619901CS
120.32961.61048689140.5341.790.301547671340.9699966CS
26-4.272-83.19376825715.1356.23740.301526050171.2044212CS
52-110.157-99.2226625833111.02115.570.301516119136.90628557CS
156-1200.337-99.92815517821201.21213.030.3015106042912.43504583CS
260-1200.337-99.92815517821201.21213.030.3015106042912.43504583CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BTCTBTC Digital Ltd
US$ 9.73
(286.11%)
53.83M
LGMKLogicMark Inc
US$ 0.2269
(70.60%)
436.7M
WKHSWorkhorse Group Inc
US$ 1.80
(51.26%)
22.2M
PAMTPAMT Corporation
 19.01
(50.75%)
864
XBPXBP Europe Holdings Inc
US$ 1.255
(38.06%)
25.63M
STIMNeuronetics Inc
US$ 0.61415
(-44.17%)
4.26M
NGNENeurogene Inc
US$ 40.15
(-43.87%)
412.65k
RAILFreightCar America Inc
US$ 9.997
(-36.37%)
1.2M
PGYPagaya Technologies Ltd
US$ 11.11
(-34.22%)
6.01M
RMTIRockwell Medical Inc
US$ 3.0811
(-33.74%)
3.24M
CEROCERo Therapeutics Holdings Inc
US$ 0.263
(34.18%)
483.97M
LGMKLogicMark Inc
US$ 0.2269
(70.60%)
439.24M
LIFWMSP Recovery Inc
US$ 0.1665
(31.41%)
137.37M
ELABElevai Labs Inc
US$ 0.0181
(-6.22%)
74.82M
NVDANVIDIA Corporation
US$ 149.08
(2.63%)
74.73M

GRI Discussion

게시물 보기
tw0122 tw0122 1 주 전
 the Company issued new unregistered Series D-1 warrants to purchase up to an aggregate of 762,236 shares of the Company’s common stock and new unregistered Series D-2 warrants to purchase up to an aggregate of 762,236 shares of the Company’s common stock. The new Series D-1 and D-2 warrants are immediately exercisable at an exercise price of $1.00 per share. The Series D-1 warrants will have a term of five years from the issuance date and the Series D-2 warrants will have a term of eighteen months from the issuance date
👍️0
tw0122 tw0122 1 주 전
Warrants at $1 ... Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, “The proceeds from the financings we have completed since the start of this year have greatly strengthened our balance sheet and are estimated to have provided the necessary funding to advance the development of our lead program into the middle of the first quarter of 2025. With these proceeds in hand and the continued progress toward interim and topline data for our lead program, expected in the coming quarters, we believe we are well positioned to realize the full potential of GRI-0621 to provide significant benefit to IPF patients.”
👍️0
glenn1919 glenn1919 2 주 전
GRI.................................https://stockcharts.com/h-sc/ui?s=GRI&p=W&b=5&g=0&id=p86431144783
👍️0
Gizzer211 Gizzer211 2 주 전
It's just his opinion
😂 1
AngusPorter AngusPorter 2 주 전
And what is that? Why not share? 
👍️0
Ratface Ratface 2 주 전
Obviously yes
👍️0
AngusPorter AngusPorter 2 주 전
Well do you know something? 
👍️0
Ratface Ratface 3 주 전
Funny reading all these posts nobody knows shit
👍 1
AngusPorter AngusPorter 3 주 전
Keeps going down, what do you think the bottom is going to be? 
👍️0
Mr. White Mr. White 3 주 전
I agree, the Nov. Earnings will be on the radar.
👍 1
zj3001 zj3001 3 주 전
Anyone seeing this chart? Looks like it's going to rip to me. Just needs to hold .96/.97 right? 


👍️0
Ratface Ratface 3 주 전
I agree hold onto your shares, we still have a nice road coming ahead.
👍 2
zj3001 zj3001 3 주 전
StockTwits bears are attacking it hard to load up. 

Using a prior offering agreement in February to scare people. 

The original agreement was for HC to purchase warrrants at 14.3 a share. However, you need to account for the reverse split of 13-1 in July (or June?). The warrants then became exercisable at $1.

New float will be 3.69m 
Adding $800k cash to balance sheets. 

Over reaction and still undervalued. 
Waiting for the chart pumpers to come in this afternoon to run it up. 

Just my 2 cents.

👍️0
Mr. White Mr. White 3 주 전
Crap. WTF
👍️0
Ratface Ratface 3 주 전
Here
👍 1
Ratface Ratface 3 주 전
Yikes
👍️0
Mr. White Mr. White 3 주 전
Me ZZZZZZzzzzz missed some money for sleeping in....damn it.
👍️0
Mr. White Mr. White 3 주 전
I see. All down..down...down...except, chart aside...they have a promising arthritis drug and a Japanese patent rights. These types of things can't be viewed on a chart. Notice pharmacy stocks at the .50 range going straight up? DRUG was .90 when I found it. GRI was .60 when I found it. Institutional intrest...or deep pockets, but serious interest 🤔
👍️0
Mr. White Mr. White 3 주 전
News after hour Could be something for tomorrow pre market,
GRI Bio Announces Exercise of Warrants
October 21 2024 - 5:35PM
🤔
👍️0
zj3001 zj3001 3 주 전
What’s thoughts on AH activity?
👍️0
Ratface Ratface 3 주 전
Chomp chomp chomp
👍️0
zj3001 zj3001 3 주 전
Again.
👍️0
zj3001 zj3001 3 주 전
Halted
👍️0
glenn1919 glenn1919 3 주 전
GRI...................................https://stockcharts.com/h-sc/ui?s=GRI&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 3 주 전
Assuming Going past $2 one more round for some quick gains for latecomers
👍️0
tw0122 tw0122 3 주 전
Cashed out on SYTA also your not too late for AMC it’s ready for 100% pump likely but no guarantees
👍️0
zj3001 zj3001 3 주 전
Small 6am cst sell off from those that slept in. Headed north! Extremely undervalued market cap.
👍️0
TheFinalCD TheFinalCD 3 주 전
GM NICE EARLY ALERTS

.87 + 50%

$GRI $0.70 - Current company valuation is less than $3 mln despite ~$6 mln cash on hand and drugs in development stages. Remember they also have library of 500+ proprietary compounds that can further enrich their drug discovery pipeline.
Recent acquisitions in IPF (Idiopathic… pic.twitter.com/CbmG68QKA8— SuperDuper Investor (@SuperDuperInvst) October 20, 2024
👍️0
tw0122 tw0122 3 주 전
$2 + 240%
👍️0
tw0122 tw0122 3 주 전
GRI 1.62 + 180% flipping out now gains secured
👍️0
tw0122 tw0122 3 주 전
GRI up 150% now
👍️0
tw0122 tw0122 3 주 전
GRI 1.44 + 150%
👍️0
tw0122 tw0122 3 주 전
$1.13 + 96%
👍️0
tw0122 tw0122 3 주 전
.87 + 50%
👍️0
zj3001 zj3001 3 주 전
Top 10 watchers on StockTwits now.
👍️0
zj3001 zj3001 3 주 전
Additional data added here…

$GRI is very transparent on their goal here. Just read between the lines, Pharma partner or Buyout incoming!

✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.

b2idigital.com/gri-bio

✅ News last week stating positive phase 2 data has been demonstrated, study on going.

gribio.com/gri-bio-presen…

✅ Phase 2 expected to be done this year (2024).

clinicaltrials.gov/study/NCT06331…

✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”

s3.amazonaws.com/sec.irpass.cc/…

✅Nasdaq compliance due by March 2025.

✅Executives have a track record of building pharma drugs/companies and selling them off. Their profiles discuss deal markers, IP protection, acquisition/mergers.

✅2.93m shares OS

✅ GRI Bio’s key executives own the following amounts of shares:

Walter Marc Hertz, CEO, holds approximately 385,510 shares.

Albert Agro, Chief Medical Officer, owns around 172,189 shares.

Vipin Chaturvedi, Chief Scientific Officer, also owns 172,189 shares.

Leanne Kelly, Chief Financial Officer, holds 83,333 shares.

Grok has this info for insiders

Based on the latest available data up to October 19, 2024, GRI Bio, Inc. (GRI) is largely owned by insiders,

- **Joseph E. Payne** owns **29.42%** of the company, making him the largest individual shareholder with 861,250 shares.
- **Arcturus Therapeutics Holdings Inc** holds **28.82%**.
- **Walter Marc Hertz** has **13.17%**.
- **Ofir Levi** owns **6.72%**.
- **Albert Agro** and **Vipin Chaturvedi** each own **5.88%**.
- **Richard Ammer** and **Pharma Gmbh Salmon** each hold **1.61%**.


👍️0
zj3001 zj3001 3 주 전
Things to note that I posted on X and ST.

✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.

✅ News last week stating positive phase 2 data has been demonstrated, study on going.

https://gribio.com/gri-bio-presents-positive-preclinical-data-demonstrating-gri-0621s-ability-to-inhibit-invariant-natural-killer-t-inkt-cell-activity-and-reduce-important-inflammatory-and-fibrotic-drivers-in-idiopa/

✅ Phase 2 expected to be done this year (2024).

https://clinicaltrials.gov/study/NCT06331624?spons=GRI%20Bio%20Operations,%20Inc.&rank=1

✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”

https://s3.amazonaws.com/sec.irpass.cc/2647/0001824293-24-000105.htm



✅Nasdaq compliance due by March 2025.

👍️0
zj3001 zj3001 3 주 전
$GRI

$PLRX appears to be working on the same IPF treatment as GRI. Both in phase2a. GRI is much further along and will be done this year yet. However, PLRX has a market cap of over $900m and 60m shares!

Both basically have this treatment as their only drug in the pipeline.

If you remove $500m in plrx “assets” from market cap, GRI should be at $400m mc.


$400m mc / 2.93m shares = $136/share!
👍️0
zj3001 zj3001 4 주 전
Yea, this is nuts. Lol
Out of all the runners the last few weeks, this one has to be tightest if true. That’s less than 205k shares
👍️0
Gizzer211 Gizzer211 4 주 전
Maybe it will pull a DRUG move
👍️0
zj3001 zj3001 4 주 전
Is there really only 2.93m shares and just over 93% is held by insiders?

How is this not going to rip to $5-20?
👍️0
mining101 mining101 4 주 전
Big times ahead
👍️0
pennyonfire pennyonfire 4 주 전
In GRI. Looks like big bounce coming
👍️0
Mdrea Mdrea 4 주 전
GRI, Let's get this moving up.
👍️ 1
tw0122 tw0122 4 주 전
RI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Source: GlobeNewswire Inc.

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).
The poster titled, “Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis,” was presented by Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio highlighting results of an analysis of bronchoalveolar lavage (BAL) fluid from IPF patients and GRI-0621 in a treatment model of pulmonary fibrosis was presented at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024) being held October 12-16, 2024 in Athens, Greece.

Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, “We continue to believe in our therapeutic targets, and this preclinical data provides further helpful insight into the effects of targeting the inhibition of iNKT cell activity in later stages of a preclinical model of IPF. We believe GRI-0621 has the potential to provide significant benefit to IPF patients and we remain focused on its advancement toward interim data and topline data from our Phase 2a biomarker study in the coming quarters.”

Key Highlights

IPF patients had increased expression in whole BAL pellets of pro-fibrotic factors as Collagen 1-a1, osteopontin and TGF-ß, as assessed by qPCR.
Researchers detected an increase in IFN-? producing NKT cells in IPF, compared to controls and confirmed iNKT cell phenotype in a second cohort, using an antibody against Va24-Ja18 of the iNKT TCR.
GRI-0621 treatment, administered during the fibrotic phase of the bleomycin model of pulmonary fibrosis, improved a majority of inflammatory, fibrotic and pathological features including a reduction in lung injury, myofibroblast activity, collagen deposition and fibrosis.
IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. The architectural destruction of the lung results in breathlessness, significant decline in quality of life and an average untreated survival of 3.5 years from diagnosis. Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on survival1.

GRI Bio is currently advancing its lead program GRI-0621, a small molecule RAR-ß? dual agonist candidate that inhibits the activity of human iNKT cells, in a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study for the treatment of IPF. Interim data from the Phase 2a biomarker study is expected in the fourth quarter of 2024 and topline results are expected in the first quarter of 2025.

👍️0
mining101 mining101 1 월 전
Nice
👍️0
Awl416 Awl416 1 월 전
Yawn…
👍️0
tw0122 tw0122 1 월 전
GRI .52 cashing all out resistance at .58
👍️0
tw0122 tw0122 1 월 전
GRI .41 +’18% 09:24 AM EDT, 09/30/2024 (MT Newswires) -- GRI Bio (GRI) said Monday it has received a "decision to grant" notice from Japan's Patent Office for a patent application covering the use of natural killer T cell modulators to prevent and treat inflammatory diseases.

The patent covers claims, which include compositions and methods, for modulating type 2 and/or type 1 invariant natural killer T cells to prevent and treat the conditions, the company said.
👍️0
mining101 mining101 1 월 전
Hui
👍️0

최근 히스토리

Delayed Upgrade Clock